TAMPA, Fla. (March 15, 2005) — Nanobac Life Sciences, Inc. (OTCBB:NNBP) today announced that it has signed a collaborative agreement with the Mayo Foundation for Medical Education and Research to conduct research relating to the prevalence and treatment of Nanobacteria in specific disease populations. The two groups will evaluate the role of Nanobacteria through four studies utilizing diagnostic test kits developed by Nanobac Oy, a wholly owned subsidiary of Nanobac Life Sciences. The studies will be conducted at Mayo.
“We are very pleased to have Mayo as a partner to research the role of Nanobacteria in diseases involving pathological calcification and to validate and expand the applications of our diagnostic ELISA assays,” said John Stanton, Nanobac’s president and CEO. “Mayo has a long history of applying the latest technologies and scientific expertise to difficult clinical questions. We look forward to a long and fruitful scientific collaboration.”
Nanobac Life Sciences, Inc. is dedicated to improving people’s health through the detection and treatment of Nanobacterium sanguineum (Nanobacteria). The Company’s pioneering research is establishing the pathogenic role of Nanobacteria in pathological calcification, particularly in coronary artery heart disease and urologic disease. Nanobac has identified two biomarkers of nanobacterial infection, and expects to file for FDA approval of its nanobacterial antigen and antibody assays. It is also leveraging its proprietary knowledge and intellectual property to develop compounds to treat nanobacterial infection. The Company currently markets a patented nanobiotic regimen. For further information concerning our nanobiotic, please visit http://www.nanobacsciences.com.
Nanobac Life Sciences, Inc. is headquartered in Tampa, Florida. For more information, please visit our website at: http://www.nanobaclifesciences.com.
Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of Nanobac Life Sciences, Inc. officials are “Forward-Looking Statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as “believes,” “anticipates,” “intends,” “plans,” “expects,” and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Life Sciences, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Life Sciences, Inc. has no specific intention to update these statements.